Summary

The Europe hepatitis B infection market is expected to reach USD 4.52 billion by 2031 from USD 3.13 billion in 2023, growing at a CAGR of 4.7% in the forecast period of 2024 to 2031.
Market Segmentation:
Europe Hepatitis B Infection Market Segmentation, By Type (Chronic and Acute), By treatment (Vaccine, Antiviral Drugs, Immune Modulator Drugs, and Surgery, By Countries (Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Denmark, Norway, Finland, Poland Turkey, and rest of Europe)- Industry Trends and Forecast to 2031

Overview of Europe Hepatitis B infection Market Dynamics:

Driver

• Increasing prevalence of hepatitis B infections
Restraint

• Side effects and drug resistance

Opportunity

• Advanced research and development for clinical trials

Market Players:

The key market players operating in the Europe hepatitis B infection market are listed below:

• GSK plc
• Gilead Sciences, Inc.
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb

ページTOPに戻る

Table of Contents

1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF EUROPE HEPATITIS B INFECTION MARKET 22
1.4 MARKETS COVERED 25
2 MARKET SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 30
2.6 MULTIVARIATE MODELLING 33
2.7 THERAPEUTICS LIFELINE CURVE 34
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.9 DBMR MARKET POSITION GRID 36
2.10 VENDOR SHARE ANALYSIS 37
2.11 SECONDARY SOURCES 38
2.12 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHT 44
4.1 PESTAL ANALYSIS 45
4.2 PORTER FIVE FORCES 46
5 EUROPE HEPATITIS B INFECTION MARKET: REGULATIONS 47
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION 47
5.2 NORTH AMERICA REGULATORY SCENARIO 55
5.3 EUROPE REGULATORY SCENARIO 63
5.4 MIDDLE EAST AND AFRICA REGULATORY SCENARIO 67
5.5 SOUTH AMERICA REGULATORY SCENARIO 72
6 PIPELINE ANALYSIS 77
7 EPIDEMILIOGY 88
8 MARKET OVERVIEW 90
8.1 DRIVERS 92
8.1.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS 92
8.1.2 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS 93
8.1.3 DEVELOPMENT OF COMBINATION THERAPIES FOR HEPATITIS B 94
8.1.4 STRATEGIC INITIATIVES BY COMPANIES FOR HEPATITIS B INFECTION 95
8.2 RESTRAINTS 96
8.2.1 SIDE EFFECTS AND DRUG RESISTANCE 96
8.2.2 INSUFFICIENT VACCINE COVERAGE FOR HEPATITIS B INFECTION 97
8.3 OPPORTUNITY 98
8.3.1 RISING NEW DRUG RELEASES AND INCREASING NEW DRUG PERMITS FOR HEPATITIS B 98
8.3.2 GOVERNMENT PROGRAMS TO RAISE AWARENESS OF HEPATITIS B INFECTION 99
8.3.3 ADVANCED RESEARCH AND DEVELOPMENT FOR CLINICAL TRIALS 100
8.4 CHALLENGES 101
8.4.1 THE COST OF HEPATITIS B TREATMENTS IS HIGH 101
8.4.2 STRINGENT REGULATORY POLICIES AND REGIONAL DISPARITIES IN TREATMENT ACCESS 102
9 EUROPE HEPATITIS B INFECTION MARKET, BY TYPE 103
9.1 OVERVIEW 104
9.2 CHRONIC 107
9.3 ACUTE 107
10 EUROPE HEPATITIS B INFECTION MARKET, BY TREATMENT 108
10.1 OVERVIEW 109
10.2 VACCINE 112
10.2.1 HOSPITAL PHARMACIES 112
10.2.2 DRUGS STORES AND RETAIL PHARMACIES 112
10.2.3 ONLINE PHARMACIES 112
10.3 ANTIVIRAL DRUGS 113
10.3.1 TENOFOVIR ALAFENAMIDE FUMARATE (TAF) 113
10.3.2 TENOFOVIR DISOPROXIL FUMARATE (TDF) 113
10.3.3 ENTECAVIR 113
10.3.4 OTHERS 113
10.4 IMMUNE MODULATOR DRUGS 114
10.4.1 PEGYLATED INTERFERON 114
10.4.2 INTERFERON ALPHA 114
10.5 SURGERY 115
11 EUROPE HEPATITIS B INFECTION MARKET, BY REGION 116
11.1 EUROPE 118
11.1.1 GERMANY 121
11.1.2 U.K 123
11.1.3 TURKEY 125
11.1.4 RUSSIA 127
11.1.5 SPAIN 129
11.1.6 ITALY 131
11.1.7 SWEDEN 133
11.1.8 BELGIUM 135
11.1.9 POLAND 137
11.1.10 FRANCE 139
11.1.11 SWITZERLAND 141
11.1.12 NETHERLANDS 143
11.1.13 NORWAY 145
11.1.14 DENMARK 147
11.1.15 FINLAND 149
11.1.16 REST OF EUROPE 151
12 EUROPE HEPATITIS B TREATMENT MARKET: COMPANY LANDSCAPE 152
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS 153
14 COMPANY PROFILE 154
14.1 GILEAD SCIENCES, INC. 154
14.1.1 COMPANY SNAPSHOT 154
14.1.2 REVENUE ANALYSIS 154
14.1.3 COMPANY SHARE ANALYSIS 155
14.1.4 PRODUCT PORTFOLIO 155
14.1.5 RECENT DEVELOPMENT 155
14.2 GLAXOSMITHKLINE PLC 157
14.2.1 COMPANY SNAPSHOT 157
14.2.2 REVENUE ANALYSIS 157
14.2.3 COMPANY SHARE ANALYSIS 158
14.2.4 PRODUCT PORTFOLIO 158
14.2.5 RECENT DEVELOPMENT 158
14.3 DYNAVAX TECHNOLOGIES CORPORATION 160
14.3.1 COMPANY SNAPSHOT 160
14.3.2 REVENUE ANALYSIS 160
14.3.3 COMPANY SHARE ANALYSIS 161
14.3.4 PRODUCT PORTFOLIO 161
14.3.5 RECENT DEVELOPMENTS 161
14.4 F. HOFFMAN-LA ROCHE LTD. 163
14.4.1 COMPANY SNAPSHOT 163
14.4.2 REVENUE ANALYSIS 163
14.4.3 COMPANY SHARE ANALYSIS 164
14.4.4 PRODUCT PORTFOLIO 164
14.4.5 RECENT DEVELOPMENTS 164
14.5 BRISTOL-MYERS SQUIBB COMPANY 165
14.5.1 COMPANY SNAPSHOT 165
14.5.2 REVENUE ANALYSIS 165
14.5.3 COMPANY SHARE ANALYSIS 166
14.5.4 PRODUCT PORTFOLIO 166
14.5.5 RECENT DEVELOPMENTS 166
14.6 ARROWHEAD PHARMACEUTICALS, INC. 167
14.6.1 COMPANY SNAPSHOT 167
14.6.2 REVENUE ANALYSIS 167
14.6.3 PRODUCT PORTFOLIO 168
14.6.4 RECENT DEVELOPMENTS 168
14.7 ARBUTUS BIOPHARMA 169
14.7.1 COMPANY SNAPSHOT 169
14.7.2 REVENUE ANALYSIS 169
14.7.3 PRODUCT PORTFOLIO 170
14.7.4 RECENT UPDATES 170
14.8 AUROBINDO PHARMA 171
14.8.1 COMPANY SNAPSHOT 171
14.8.2 REVENUE ANALYSIS 171
14.8.3 PRODUCT PORTFOLIO 172
14.8.4 RECENT UPDATES 172
14.9 LUPIN PHARMACEUTICALS, INC. 173
14.9.1 COMPANY SNAPSHOT 173
14.9.2 PRODUCT PORTFOLIO 173
14.9.3 RECENT UPDATES 174
14.10 MERCK & CO., INC., 175
14.10.1 COMPANY SNAPSHOT 175
14.10.2 REVENUE ANALYSIS 175
14.10.3 PRODUCT PORTFOLIO 176
14.10.4 RECENT DEVELOPMENTS 176
14.11 NOVARTIS AG 177
14.11.1 COMPANY SNAPSHOT 177
14.11.2 REVENUE 177
14.11.3 PRODUCT PORTFOLIO 178
14.11.4 RECENT DEVELOPMENT 178
14.12 TEVA PHARMACEUTICAL INDUSTRIES 179
14.12.1 COMPANY SNAPSHOT 179
14.12.2 PRODUCT PORTFOLIO 179
14.12.3 RECENT DEVELOPMENTS 179
14.13 ZYDUS PHARMACEUTICALS, INC. 180
14.13.1 COMPANY SNAPSHOT 180
14.13.2 PRODUCT PORTFOLIO 180
14.13.3 REVENUE 181
14.13.4 RECENT DEVELOPMENT 181
15 QUESTIONNAIRE 182
16 RELATED REPORTS 184